Study Conducted At Boston University
Results Published in Journal of Periodontology
Results Indicated Compound Could Be Major Breakthrough In Prevention Of Periodontal Disease

SAN DIEGO, June 1 /PRNewswire/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the first scientific publication of a study that was conducted on its proprietary compound, 1-TDC, for the [...]

{ Comments on this entry are closed }

92% Improvement In Lowering Body Fat
62% Improvement In Reducing Waist Circumference

SAN DIEGO, May 22 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today that results from the recently completed study at the University of Connecticut on its patented body fat reduction ingredient, Trisynex, were presented at two scientific conferences.
“We are extremely pleased [...]

{ Comments on this entry are closed }

Revenues For Fourth Fiscal Quarter Almost Double Third Fiscal Quarter And Same Quarter Of Prior Year
Expects Celadrin(R) To Be In 10,000 Retail Stores By The End Of The Quarter
Quigley-Simpson Engaged To Assist In Promotion Of Retail Launch

SAN DIEGO, April 13 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced [...]

{ Comments on this entry are closed }

Imagenetix Reports Third Quarter Fiscal Results

by Imagenetix on February 14, 2007

SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the results for its third fiscal quarter ended December 31, 2006. Net sales for the third fiscal quarter were $1,062,000, a decrease of 39.1% from the $1,743,000 reported for the same period of the prior fiscal year. The Company [...]

{ Comments on this entry are closed }

SAN DIEGO–(BUSINESS WIRE)–Imagenetix, Inc. (OTCBB: IAGX – News) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has completed pre-IND assessment by the FDA Dental and Dermatology Division and received positive comments.
The FDA response, issued after reviewing animal toxicity, animal [...]

{ Comments on this entry are closed }